Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTL0812 plus FOLFIRINOX versus placebo plus FOLFIRINOX in metastatic pancreatic cancer
MOH_2021-10-18_010273Phase 2Completed
- Sponsor
- AbilityPharma
- Start
- Sep 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC) comparing ABTL0812 + FOLFIRINOX with Placebo + FOLFIRINOX (2 arms). Primary endpoint: Progression-free survival. Started Sep 2021; status: completed.
02
Drugs
ibrilatazar
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on MOH_2021-10-18_010273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-18_010273.